Lilly executive says China could approve its GLP-1 pill in 2026
An oral incretin approval in China would open the world's second-largest pharmaceutical market to Lilly's tablet ahead of most rivals.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 24 03:00 ETSource: Reuters
The wire
- 01A Lilly executive told Reuters that Chinese regulatory approval for the company's oral GLP-1 could come as soon as 2026.
- 02China is a major obesity and diabetes market where an oral option avoids cold-chain and injection-supply constraints that shaped earlier GLP-1 launches.
- 03Timing rests on a company executive's statement rather than a regulatory decision; pricing, reimbursement and local supply plans were not detailed.
From the source
Read at reuters.comChina approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says